Trials / Terminated
TerminatedNCT01057901
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 748 (actual)
- Sponsor
- Sprout Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flibanserin | Flibanserin 100mg administered at bedtime for 24 weeks |
| DRUG | Placebo | This is the matched placebo which will be administered two tablets daily at bedtime. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2010-01-28
- Last updated
- 2014-06-17
- Results posted
- 2014-06-17
Locations
100 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01057901. Inclusion in this directory is not an endorsement.